Davis Polk advised Oryzon Genomics, S.A. on its €20 million private placement of its ordinary shares pursuant to a capital increase. The offering consisted of a private placement to qualified investors in the United States and Europe.

Oryzon is a clinical-stage biopharmaceutical company focused on epigenetic therapies for a variety of malignant and neurodegenerative diseases.

The Davis Polk corporate team included partners Michael J. Willisch, Marcel Fausten, Simon Witty and Dan Hirschovits and associates Marcelo Valenca and Jose Lucena-Rebollo. Associate Matthew R. Silver provided 1940 Act advice. Members of the Davis Polk team are based in the Madrid, London and New York offices.

Copy link to share post